+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hypertrophy Medication Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Benign Prostatic Hypertrophy Medication Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Benign Prostatic Hypertrophy Medication Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6080410
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The benign prostatic hypertrophy (BPH) medication arena stands at a pivotal moment. As the aging male population grows and clinical understanding deepens, stakeholders face a confluence of opportunities and complexities. Historically dominated by established classes such as 5-alpha reductase inhibitors and alpha blockers, the market is now witnessing a surge of novel formulations, combination regimens, and non-medication procedures. Technological advances in drug delivery, coupled with evolving patient expectations for efficacy and tolerability, are driving a transformation in treatment paradigms. Meanwhile, regulatory landscapes and reimbursement frameworks are adapting in response to shifting healthcare budgets and value-based care initiatives. Consequently, decision-makers require an integrated perspective that balances therapeutic innovation, economic pressures, and patient-centric considerations. This executive summary provides a concise yet comprehensive overview of the forces reshaping the BPH medication market, laying the groundwork for strategic insights that guide investment, development, and commercialization strategies throughout the healthcare ecosystem.

Transformative Shifts Reshaping the BPH Medication Market

Over the past decade, the BPH therapeutic landscape has undergone transformative shifts driven by demographic, technological, and regulatory catalysts. With life expectancy on the rise, a larger cohort of men enters age brackets associated with prostate enlargement, reinforcing demand for both preventive and symptomatic interventions. Moreover, combination therapies that integrate 5-alpha reductase inhibitors with alpha blockers have gained traction by demonstrating superior symptom relief and reduced progression rates. At the same time, advancements in minimally invasive procedures, such as water vapor thermal therapies, are challenging the monopoly of traditional surgical approaches.

Digital health platforms have become integral to monitoring patient adherence and symptom progression, enabling clinicians to tailor therapies with real-time feedback. Simultaneously, telemedicine has streamlined patient access to secondary treatments provided by urologists and general practitioners alike, particularly in underserved regions. On the regulatory front, agencies in key markets are expediting review pathways for breakthrough formulations with favorable safety profiles, notably those with low side-effect burdens and long-term efficacy. Lastly, payer policies are increasingly aligning reimbursement with value metrics, incentivizing therapies that reduce hospitalizations and surgical interventions. Taken together, these shifts are redefining competitive dynamics, requiring companies to adopt agile, patient-driven strategies that emphasize real-world performance and cost-efficiency.

Assessing the Cumulative Impact of U.S. Tariffs in 2025 on BPH Medication

In 2025, newly imposed tariffs on pharmaceutical components and finished products in the United States have introduced additional cost considerations across the BPH medication value chain. Ingredients imported for manufacturing 5-alpha reductase inhibitors and phosphodiesterase-5 enzyme inhibitors now carry higher landed costs, compelling some manufacturers to reevaluate sourcing strategies. Consequently, formulators of oral tablets-whether extended-release or immediate-release-face margin compression unless they secure alternative suppliers or negotiate volume-based discounts. In parallel, manufacturers of topical treatments and injectables are exploring onshore production partnerships to mitigate tariff impacts and ensure supply continuity.

Distribution channels such as hospital pharmacies and retail outlets are experiencing slight price adjustments, prompting payers to scrutinize reimbursement levels for both medication and non-medication therapies. Online pharmacies, which often operate under leaner cost structures, are capitalizing on tariff-driven pricing disparities to capture incremental market share. Meanwhile, homecare providers that offer minimally invasive procedures are evaluating the net effect on out-of-pocket expenses for patients, which could influence procedure uptake rates. Ultimately, the cumulative tariff burden highlights the importance of supply chain resilience, integrated pricing models, and collaborative dialogues with regulators to minimize disruptions and sustain patient access.

Key Segmentation Insights Driving Market Dynamics

Dissecting the market through multiple lenses reveals nuanced insights essential for targeted strategy. From a therapy-type perspective, medication interventions encompass four primary drug classes-5-alpha reductase inhibitors, alpha blockers, combination drugs, and phosphodiesterase-5 enzyme inhibitors-while non-medication therapies split into minimally invasive and surgical procedures; each segment varies in adoption depending on clinical guidelines and patient preferences. Application analysis highlights the roles of general practitioners in initial diagnosis and management, alongside urologists who administer advanced secondary treatments and procedural care. Examining distribution channels uncovers distinct dynamics within hospital pharmacies, online pharmacies, and retail pharmacies, where factors such as formulary inclusion, digital outreach, and patient loyalty programs drive volume.

Formulation choices also shape competitive positioning: injectables cater to rapid symptom relief but require healthcare professional administration, oral tablets-available in immediate-release and extended-release forms-offer convenience and adherence support, and topical treatments aim to minimize systemic exposure. Patient demographics further stratify the market, with age groups ranging from under 50 years to 70 years and above, and health condition classifications spanning mild, moderate, and severe symptom severity. End-user categories illustrate different care settings, including clinics, homecare environments, and hospitals (both private and public), each presenting unique reimbursement models and operational requirements. Finally, efficacy profiles differentiate products by long-term versus short-term outcomes, while side-effect profiles-high, moderate, or low-often govern prescribing behavior and patient satisfaction. Integrating these segmentation insights enables stakeholders to pinpoint growth pockets, optimize resource allocation, and craft tailored value propositions.

Regional Dynamics: Core Insights Across Major Geographies

Geographic variations play a pivotal role in shaping the BPH medication market. In the Americas, robust healthcare infrastructure, comprehensive insurance coverage, and favorable regulatory frameworks underpin high adoption rates of both advanced medication classes and minimally invasive procedures; this region also serves as a testing ground for digital health integrations and real-world evidence initiatives. Conversely, Europe, Middle East & Africa present a diverse tapestry of challenges and opportunities: Western European countries exhibit mature biosimilar markets and evolving value-based reimbursement models, while emerging markets in the Middle East and Africa are characterized by growing patient awareness, constrained budgets, and collaboration opportunities with non-governmental organizations to enhance screening and treatment access.

Asia-Pacific stands out for its rapidly aging societies, particularly in Japan, South Korea, and China, where demand for oral tablet formulations-especially extended-release options-has surged. These markets are also witnessing rising investments in local manufacturing to serve domestic and export needs. Regulatory harmonization efforts within regional blocs are easing market entry for novel combination therapies, while online pharmacy growth, driven by digital-savvy populations, is reshaping distribution paradigms. By understanding these regional nuances-ranging from payer policies to patient behavior-industry leaders can deploy differentiated strategies that optimize product positioning, supply chain efficiencies, and stakeholder engagement.

Competitive Landscape: Key Company Insights

The competitive landscape is dominated by a diverse set of pharmaceutical and biotech players, each leveraging unique strengths. AbbVie Inc. continues to expand its alpha blocker portfolio through strategic licensing agreements, while Allergan plc is investing in next-generation combination therapies designed to enhance long-term outcomes. Astellas Pharma Inc. is broadening its footprint in minimally invasive procedural devices, complementing its established drug offerings.

Boehringer Ingelheim and Eli Lilly and Company are collaborating on novel phosphodiesterase-5 enzyme inhibitors with refined safety profiles, whereas Dr. Reddy’s Laboratories Ltd. is focusing on cost-effective generics to capture price-sensitive segments. Ferring Pharmaceuticals has prioritized real-world evidence studies to validate long-term efficacy claims, and GlaxoSmithKline plc is integrating digital adherence tools to support patient engagement. Merck & Co., Inc. and Mylan N.V. are optimizing their distribution partnerships across hospital and retail pharmacies, ensuring broad market coverage. Meanwhile, Novartis International AG is researching injectable formulations for rapid symptom management, and Pfizer Inc. is exploring topical treatments to address systemic side-effect concerns.

Sanofi S.A. is strengthening its glandular device pipeline, whereas Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd. are competing in oral tablet generics and extended-release technologies. Finally, Zydus Cadila is targeting emerging markets with tailored pricing models and local manufacturing, demonstrating the strategic importance of agility in dynamic regulatory environments. These collective movements underscore a market in flux, where differentiation hinges on innovation, cost management, and collaborative ecosystems.

Actionable Recommendations for Industry Leaders

To capitalize on emerging opportunities, industry leaders should adopt a multi-pronged approach. First, prioritizing research and development in combination therapies that deliver superior symptom relief while minimizing side effects will meet growing clinician and patient demands. Second, integrating digital health solutions-such as remote monitoring platforms and adherence apps-can strengthen real-world evidence generation and foster deeper patient engagement.

Third, adopting adaptive pricing strategies that align with value-based reimbursement models will be critical, particularly in markets experiencing tariff pressures or budget constraints. Fourth, collaborating with regulatory bodies early in the development cycle can streamline approvals and anticipate policy shifts, ensuring timely market entry. Fifth, fortifying supply chain resilience through diversified sourcing and onshore manufacturing partnerships will mitigate the impact of external disruptions, including tariffs and geopolitical uncertainties.

Sixth, expanding presence in underpenetrated geographies by leveraging local distribution networks and strategic alliances can unlock incremental growth. Seventh, investing in patient education initiatives in both clinical and non-clinical settings will enhance screening rates and therapy adherence. Lastly, forging cross-sector collaborations with technology providers, healthcare payers, and advocacy groups will create integrated care pathways that underscore the value proposition of novel BPH interventions.

Conclusion and Strategic Implications

In summary, the BPH medication market is evolving under the influence of demographic trends, technological advancements, and shifting regulatory frameworks. As the prevalence of prostate enlargement rises, manufacturers and care providers must navigate complex segmentation variables, regional disparities, and competitive pressures. The 2025 U.S. tariff adjustments underscore the necessity of supply chain agility and value-aligned pricing strategies, while regional insights highlight distinct pathways for growth in the Americas, EMEA, and Asia-Pacific.

Key companies are differentiating through innovation in drug classes, device integration, digital health, and evidence generation. Moving forward, success will hinge on the ability to anticipate payer mandates, collaborate across stakeholder ecosystems, and maintain an unwavering focus on patient outcomes. By synthesizing segmentation, regional, and competitive insights, decision-makers can craft holistic strategies that balance short-term performance with long-term resilience, ensuring sustained leadership in a dynamic market.

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hypertrophy Medication Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Medication
    • 5-Alpha Reductase Inhibitors
    • Alpha Blockers
    • Combination Drugs
    • Phosphodiesterase-5 Enzyme Inhibitors
  • Non-Medication Therapies
    • Minimally Invasive Procedures
    • Surgical Procedures
  • Secondary Treatments
    • General Practitioners
    • Urologists
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Injectables
  • Oral Tablets
    • Extended Release
    • Immediate Release
  • Topical Treatments
  • Age Groups
    • 50-59 Years
    • 60-69 Years
    • 70 Years and Above
    • Under 50 Years
  • Health Condition
    • Mild Symptoms
    • Moderate Symptoms
    • Severe Symptoms
  • Clinics
  • Homecare
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Long-Term Efficacy
  • Short-Term Efficacy
  • High Side Effects
  • Low Side Effects
  • Moderate Side Effects

This research report categorizes the Benign Prostatic Hypertrophy Medication Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Benign Prostatic Hypertrophy Medication Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Allergan plc
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benign Prostatic Hypertrophy Medication Market, by Therapy Type
8.1. Introduction
8.2. Medication
8.2.1. 5-Alpha Reductase Inhibitors
8.2.2. Alpha Blockers
8.2.3. Combination Drugs
8.2.4. Phosphodiesterase-5 Enzyme Inhibitors
8.3. Non-Medication Therapies
8.3.1. Minimally Invasive Procedures
8.3.2. Surgical Procedures
9. Benign Prostatic Hypertrophy Medication Market, by Application
9.1. Introduction
9.2. Secondary Treatments
9.2.1. General Practitioners
9.2.2. Urologists
10. Benign Prostatic Hypertrophy Medication Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Benign Prostatic Hypertrophy Medication Market, by Formulation
11.1. Introduction
11.2. Injectables
11.3. Oral Tablets
11.3.1. Extended Release
11.3.2. Immediate Release
11.4. Topical Treatments
12. Benign Prostatic Hypertrophy Medication Market, by Patient Demographics
12.1. Introduction
12.2. Age Groups
12.2.1. 50-59 Years
12.2.2. 60-69 Years
12.2.3. 70 Years and Above
12.2.4. Under 50 Years
12.3. Health Condition
12.3.1. Mild Symptoms
12.3.2. Moderate Symptoms
12.3.3. Severe Symptoms
13. Benign Prostatic Hypertrophy Medication Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Homecare
13.4. Hospitals
13.4.1. Private Hospitals
13.4.2. Public Hospitals
14. Benign Prostatic Hypertrophy Medication Market, by Efficacy
14.1. Introduction
14.2. Long-Term Efficacy
14.3. Short-Term Efficacy
15. Benign Prostatic Hypertrophy Medication Market, by Side Effects Profile
15.1. Introduction
15.2. High Side Effects
15.3. Low Side Effects
15.4. Moderate Side Effects
16. Americas Benign Prostatic Hypertrophy Medication Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Benign Prostatic Hypertrophy Medication Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Benign Prostatic Hypertrophy Medication Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Allergan plc
19.3.3. Astellas Pharma Inc.
19.3.4. Boehringer Ingelheim
19.3.5. Dr. Reddy's Laboratories Ltd.
19.3.6. Eli Lilly and Company
19.3.7. Ferring Pharmaceuticals
19.3.8. GlaxoSmithKline plc
19.3.9. Merck & Co., Inc.
19.3.10. Mylan N.V.
19.3.11. Novartis International AG
19.3.12. Pfizer Inc.
19.3.13. Sanofi S.A.
19.3.14. Sun Pharmaceutical Industries Ltd.
19.3.15. Teva Pharmaceutical Industries Ltd.
19.3.16. Zydus Cadila
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PHOSPHODIESTERASE-5 ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MINIMALLY INVASIVE PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY GENERAL PRACTITIONERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY UROLOGISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 50-59 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 60-69 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY UNDER 50 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MILD SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MODERATE SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SEVERE SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY LONG-TERM EFFICACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SHORT-TERM EFFICACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HIGH SIDE EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY LOW SIDE EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MODERATE SIDE EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 105. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 106. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 110. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 112. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 113. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 114. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 115. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 116. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 119. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 120. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 182. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 183. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 184. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 185. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 187. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 190. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 191. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 192. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 193. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 196. CHINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 197. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 198. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 199. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 202. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 204. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 205. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 207. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 208. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 210. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 211. INDIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 227. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 229. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 230. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 232. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 234. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 235. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 237. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 238. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 240. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 241. JAPAN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY EFFICACY, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SIDE EFFECTS PROFILE, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY NON-MEDICATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY SECONDARY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 277. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 279. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 280. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUPS, 2018

Companies Mentioned

  • AbbVie Inc.
  • Allergan plc
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sodium Aluminum Belladonna Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Sodium Aluminum Belladonna Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global, United States Global, United States
From
Benign Prostatic Hypertrophy Drugs Market by Product, Sales Channel - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hypertrophy Drugs Market by Product, Sales Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Drugs for Benign Prostatic hypertrophy Market Report 2025 - Product Image

Drugs for Benign Prostatic hypertrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2025 - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.